Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies

Phase 1 Completed 24 enrolled Mundipharma K.K.

NaSingle-groupOpen-labelTreatment

Summary

Primary objectives are to evaluate the safety profile and tolerability of oral BCX1777 in each cohort of patients with recurrent or refractory T/NK-cell malignancies and to evaluate pharmacokinetics (PK) of oral BCX1777.

Timeline

Start: 2009-01
Primary completion: 2013-08
Completion: —

Publications

Ogura M, Tsukasaki K, Nagai H, Uchida T, Oyama T, Suzuki T, Taguchi J, Maruyama D, Hotta T, Tobinai K. Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies. Cancer Sci. 2012 Jul;103(7):1290-5. doi: 10.1111/j.1349-7006.2012.02287.x. Epub 2012 Apr 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	forodesine	Small molecule	100 mg	Oral
Subject	forodesine	Small molecule	200 mg	Oral
Subject	forodesine	Small molecule	300 mg	Oral
Subject	forodesine	Small molecule	400 mg	Oral

Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies

Summary

Timeline

Publications

Drugs

Indications